Naratuximab

Modify Date: 2024-01-06 20:30:05

Naratuximab structure	Common Name	Naratuximab
	CAS Number	1622327-39-2	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Naratuximab

Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine[1].

Name	Naratuximab

Description	Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
In Vitro	Naratuximab emtansine (IMGN529)，一种 ADC，由 DM1 通过与 Kadcyla 中使用的相同接头连接到人源化抗 CD37 抗体组成。 Naratuximab emtansine 有效地将其抗体成分的内在促凋亡和效应活性与美登木素有效载荷的细胞毒活性结合起来[1]。
References	[1]. Stuart W Hicks, et al. The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models. Neoplasia. 2017 Sep;19(9):661-671.

No Any Chemical & Physical Properties

Naratuximab

Use of Naratuximab

Names

Naratuximab Biological Activity

Chemical & Physical Properties